AR098996A1 - Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina - Google Patents

Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina

Info

Publication number
AR098996A1
AR098996A1 ARP140104955A ARP140104955A AR098996A1 AR 098996 A1 AR098996 A1 AR 098996A1 AR P140104955 A ARP140104955 A AR P140104955A AR P140104955 A ARP140104955 A AR P140104955A AR 098996 A1 AR098996 A1 AR 098996A1
Authority
AR
Argentina
Prior art keywords
composite formulation
administration
rosuvastatina
ezetimiba
rosuvastatin
Prior art date
Application number
ARP140104955A
Other languages
English (en)
Inventor
Hyun Cho Jung
Cheul Kim Jin
Il Kim Yong
Jun Lee Seung
Hyun Park Jae
Soo Woo Jong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53791740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR098996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR098996A1 publication Critical patent/AR098996A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método de preparar la formulación compuesta. Reivindicación 1: Una formulación compuesta sólida para la administración por vía oral, comprendiendo la formulación compuesta sólida una parte de gránulos de ezetimiba que incluye ezetimiba, donde dicha ezetimiba tiene una distribución del tamaño de partícula en la que el tamaño medio de partícula d₍₀,₉₎ para el margen inferior de 90% es de aproximadamente 10 mm o menor; y una parte de mezcla de rosuvastatina que incluye rosuvastatina o una sal farmacéuticamente aceptable de la misma. Reivindicación 6: La formulación compuesta sólida de una cualquiera de las reivindicaciones 1 a 3, en donde la parte de mezcla de rosuvastatina comprende, además, un estabilizador de carácter débilmente básico.
ARP140104955A 2013-12-30 2014-12-30 Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina AR098996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20130167156 2013-12-30

Publications (1)

Publication Number Publication Date
AR098996A1 true AR098996A1 (es) 2016-06-22

Family

ID=53791740

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104955A AR098996A1 (es) 2013-12-30 2014-12-30 Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina

Country Status (25)

Country Link
US (1) US10434067B2 (es)
EP (1) EP3089739A4 (es)
JP (1) JP2017500303A (es)
KR (2) KR20150079373A (es)
CN (1) CN105873571B (es)
AR (1) AR098996A1 (es)
AU (1) AU2014374552B2 (es)
CA (1) CA2933178A1 (es)
CL (1) CL2016001654A1 (es)
CR (1) CR20160293A (es)
DO (1) DOP2016000159A (es)
GT (1) GT201600137A (es)
MX (1) MX2016008725A (es)
MY (1) MY187637A (es)
NI (1) NI201600093A (es)
PE (1) PE20161072A1 (es)
PH (1) PH12016501196A1 (es)
RU (1) RU2683937C2 (es)
SG (1) SG10201805657PA (es)
SV (1) SV2016005236A (es)
TW (1) TWI655944B (es)
UA (1) UA117685C2 (es)
UY (1) UY35932A (es)
WO (1) WO2015102400A1 (es)
ZA (1) ZA201603934B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005350A (es) * 2015-10-30 2018-08-14 Cancer Prevention Pharmaceuticals Inc Formulacion de combinacion de dosis fija, eflornitina y sulindaco.
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
CZ2016539A3 (cs) * 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
KR101910902B1 (ko) * 2016-11-03 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
JP6848469B2 (ja) * 2017-01-20 2021-03-24 ニプロ株式会社 エゼチミブ含有医薬組成物の製造方法
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
KR102569271B1 (ko) * 2018-03-19 2023-08-23 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
BR112022001783A2 (pt) * 2019-07-31 2022-03-22 Tecnimede Soc Tecnico Medicinal Sa Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
BR112023003323A2 (pt) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd Composição farmacêutica em forma de dosagem única
CN112999178A (zh) * 2021-03-01 2021-06-22 乐普制药科技有限公司 一种依折麦布匹伐他汀钙复方双层片剂
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE59409631D1 (de) 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE60106489T2 (de) 2000-12-20 2005-10-13 Schering Corp. Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
TWI337083B (en) 2001-01-26 2011-02-11 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PL366851A1 (en) 2001-08-22 2005-02-07 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
US20050026992A1 (en) 2003-07-28 2005-02-03 Sasmal Badal Kumar Treatment and prevention of cardiovascular events
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070275052A1 (en) 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
EP2125715A2 (en) 2007-01-24 2009-12-02 Krka Process for the preparation of ezetimibe and derivatives thereof
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
AU2008281640A1 (en) 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CN102112440A (zh) 2008-05-30 2011-06-29 武田药品工业株式会社 杂环化合物
KR101283147B1 (ko) 2008-06-27 2013-07-05 아브디 이브라힘 이라크 사나이 베 티카레트 아노님 시르케티 로수바스타틴 칼슘의 약학적 조성물
PL2229938T3 (pl) 2009-03-13 2012-09-28 Sanovel Ilac Sanayi Ve Ticaret As Kompozycje ezetymibu
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
WO2011019326A2 (en) 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
MX365046B (es) * 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
WO2013176455A1 (ko) * 2012-05-22 2013-11-28 건일제약 주식회사 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
RU2016123828A (ru) 2018-02-07
DOP2016000159A (es) 2016-12-15
KR20150079454A (ko) 2015-07-08
MX2016008725A (es) 2017-02-28
TW201609091A (zh) 2016-03-16
CR20160293A (es) 2016-10-05
US20160346213A1 (en) 2016-12-01
UY35932A (es) 2015-07-31
WO2015102400A1 (en) 2015-07-09
US10434067B2 (en) 2019-10-08
CL2016001654A1 (es) 2017-01-06
CA2933178A1 (en) 2015-07-09
PH12016501196B1 (en) 2016-08-15
TWI655944B (zh) 2019-04-11
NI201600093A (es) 2016-07-22
GT201600137A (es) 2018-10-19
RU2016123828A3 (es) 2018-08-28
CN105873571B (zh) 2019-10-22
PE20161072A1 (es) 2016-11-04
UA117685C2 (uk) 2018-09-10
AU2014374552B2 (en) 2019-09-19
SG10201805657PA (en) 2018-08-30
EP3089739A4 (en) 2017-08-02
ZA201603934B (en) 2017-09-27
PH12016501196A1 (en) 2016-08-15
CN105873571A (zh) 2016-08-17
MY187637A (en) 2021-10-05
EP3089739A1 (en) 2016-11-09
JP2017500303A (ja) 2017-01-05
SV2016005236A (es) 2016-11-03
AU2014374552A1 (en) 2016-06-02
RU2683937C2 (ru) 2019-04-03
KR20150079373A (ko) 2015-07-08

Similar Documents

Publication Publication Date Title
AR098996A1 (es) Formulación compuesta para la administración por vía oral que comprende ezetimiba y rosuvastatina
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CL2015003117A1 (es) Modificaciones en la estructura cristalina
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
PH12015501753A1 (en) Enhanced stability of novel liquid compositions
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
CL2015002702A1 (es) Composiciones farmacéuticas micronizadas.
MX362905B (es) Tratamiento de combinacion.
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
ECSP17008187A (es) Formas de dosificación farmacéutica
PH12015501313A1 (en) Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration
PH12015502029A1 (en) Phenylephrine resinate particles and use thereof in pharmaceutical formulations
UY34895A (es) Formulaciones estabilizadas de etanercept
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
PH12015502015B1 (en) Coated phenylephrine particles and use thereof in pharmaceutical formulations
IN2013MU03656A (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure